Michael Kopach, PhD

Associate Vice President at Eli Lilly and Company

Speaker

Dr. Michael Kopach is an Associate Vice President of Chemistry in Synthetic Molecule Design and Development at Eli Lilly and Company. With over 25 years of experience in the pharmaceutical industry, Mike has been with Lilly since 2001. Prior to Lilly, he worked at Roche, where he played a key role in commercializing Fuzeon, the first synthetic peptide produced on a tonnage scale for the treatment of AIDS.

At Lilly, Mike has held a variety of roles, most recently leading the commercial route development and launch of the synthetic peptide Mounjaro/Zepbound. He currently serves as the Drug Substance Lead for Lilly’s Phase 3 triagonist Retatrutide, which is under evaluation for chronic weight management.

In addition to his technical contributions, Mike has been at the forefront of Lilly’s sustainability efforts for the past two decades. He was recently nominated for a third term as co-chair of the ACS Pharmaceutical Roundtable.